<DOC>
	<DOCNO>NCT02317159</DOCNO>
	<brief_summary>This efficacy safety study imatinib Mesylate Capsule First line treatment patient chronic phase Chronic Myeloid Leukemia .</brief_summary>
	<brief_title>Efficacy Safety Imatinib Mesylate First-line Treatment Patients With Chronic Phase Chronic Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Age≥18； The new diagnosis CML patient six months； No proof extramedullary infiltration leukemia； ECOG PS score：02； Hepatic renal function normal，Serum bilirubin≤1.5*ULN , serum ALT AST≤2.5*ULN , serum Cr≤1.5*ULN ; Do receive treatment antiCML； Subjects sign informed consent form line GCP requirements。 Pregnant lactating women； Received TKIs time before； Failure control systemic infection multiple organ failure； According investigator 's judgment , concomitant disease serious safety hazard affect patient complete study； Being diagnose malignancy prior 12 months； Have history neurological psychiatric disorder , include epilepsy dementia； Known suspect allergy imatinib； BSA≤1.5m2； Using experimental drug participate clinical trial prior one months。</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>